Swedish Orphan Biovitrum AB (publ) (0MTD.IL)
| Chiusura precedente | 243,05 |
| Aperto | 243,10 |
| Denaro | 237,40 x 0 |
| Lettera | 247,70 x 0 |
| Min-Max giorno | 241,90 - 244,20 |
| Intervallo di 52 settimane | 194,47 - 249,00 |
| Volume | |
| Media Volume | 108.233 |
| Capitalizzazione | 71,955B |
| Beta (5 anni mensile) | 0,39 |
| Rapporto PE (ttm) | 24,59 |
| EPS (ttm) | 9,89 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Sobi Receives Approval from Health Canada for Empaveli™ (pegcetacoplan) for the Treatment of Certain Patients with Paroxysmal Nocturnal Hemoglobinuria
The first targeted C3 therapy approved in CanadaApproval based on results from head-to-head PEGASUS phase 3 study where Empaveli™ demonstrated superiority to eculizumab in improving hemoglobin levels1On trial, transfusion avoidance was achieved by 85.4% patients in the Empaveli group versus 15.4% in the eculizumab group1 WALTHAM, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), announced today that Health
- GlobeNewswire
U.S. Food and Drug Administration Issues Emergency Use Authorization for KINERET® (anakinra) for the Treatment of COVID-19-Related Pneumonia
Early treatment with KINERET reduced disease progression by 64 percent in hospitalized COVID-19 patientsi WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for KINERET® (anakinra) for the treatment of Coronavirus Disease 2019 (COVID-19) in adult patients who are hospitalized with positive results of d
- GlobeNewswire
Sobi to Present Data from REAL-HLH Study at the ACR Convergence 2022 Meeting
Data presented from the REAL-HLH study; the first study of patients treated with Gamifant in a real-world clinical settingWALTHAM, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of the Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI), a specialized international biopharmaceutical company transforming the lives of people with rare diseases, today announced a presentation from the REAL-HLH study – a chart review study which assessed real-world treatm
